Unicycive Therapeutics (UNCY)
US Market

Unicycive Therapeutics (UNCY) Stock Price & Analysis


UNCY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.40 - $2.87
Previous Close$1.91
Average Volume (3M)6.08M
Market Cap
Enterprise Value$22.00M
Total Cash (Recent Filing)$7.01M
Total Debt (Recent Filing)$194.00K
Price to Earnings (P/E)-1.9
Mar 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding15,088,670
10 Day Avg. Volume173,913
30 Day Avg. Volume6,076,585
Standard Deviation0.14
Financial Highlights & Ratios
Price to Book (P/B)1.73
Price to Sales (P/S)8.41
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.14
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.43
Price Target Upside318.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $0.40 and its highest was $2.87 in the past 12 months.
    What is Unicycive Therapeutics’s market cap?
    Currently, no data Available
    When is Unicycive Therapeutics’s upcoming earnings report date?
    Unicycive Therapeutics’s upcoming earnings report date is Mar 30, 2023 which is in 5 days.
      How were Unicycive Therapeutics’s earnings last quarter?
      Unicycive Therapeutics released its earnings results on Nov 14, 2022. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.09.
        Is Unicycive Therapeutics overvalued?
        According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Unicycive Therapeutics pay dividends?
          Unicycive Therapeutics does not currently pay dividends.
          What is Unicycive Therapeutics’s EPS estimate?
          Unicycive Therapeutics’s EPS estimate is -$0.26.
            How many shares outstanding does Unicycive Therapeutics have?
            Unicycive Therapeutics has 15,088,670 shares outstanding.
              What happened to Unicycive Therapeutics’s price movement after its last earnings report?
              Unicycive Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went down -5.556%.
                Which hedge fund is a major shareholder of Unicycive Therapeutics?
                Currently, no hedge funds are holding shares in UNCY


                Unicycive Therapeutics Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Unicycive Therapeutics

                Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.


                Top 5 ETFs holding UNCY

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold UNCY. The ETFs are listed according to market value of UNCY within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Theriva Biologics
                Silo Pharma
                Lixte Biotechnology Holdings
                Innovation Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis